IFN | AZA | NT | |
No of patients | 11 | 10 | 111-150 |
Sex (M/F) | 3/8 | 2/8 | 3/8 |
Age at entry (y) | 33 (6.2) | 31.2 (4.9)1-151 | 38 (6.3)1-151 |
Disease duration (y) | 8.3 (5) | 6.95 (6.7) | 8.4 (6.81-150) |
EDSS at entry | 2.32 (0.9) | 2.35 (0.9) | 1.83 (1.15) |
At 12 months | 2.2 (1.05) | 2.1 (0.9) | 1.9 (1.3) |
No of worsened patients at 12 months | 1/11 | 0/10 | 2/10 |
RF 2 year pretreatment | 2.2 (0.8)1-151 | 2 (1) | 1.4 (0.3)1-151 |
At 12 months | 0.8 (0.7)1-152 | 0.9 (0.4)1-152 | 1.0 (0.9) |
No of relapse free patients at 12 months | 4/11 | 7/10 | 4/10 |
PHC at entry | 68.02 (9.1) | 61.7 (10.8) | 61.7 (11.7) |
Change at 12 months | −2.64 (9.26) | +7.9 (9.9) | +3.66 (13.7) |
MHC at entry | 74.7 (15.7) | 61.25 (14.15) | 58.7 (16.9) |
Change at 12 months | −6.04 (13.9)1-151 | +21.25 (11.9)1-151 | +6.37 (21.8) |
RLE at entry | 83.34 (32.4) | 37.5 (33.05) | 55.55 (40.8) |
Change at 12 months | −10 (35.3)1-151 | +49.9 (35.6)1-151 | +16.6 (53.4) |
IFN=Interferonβ-1b treated patients; AZA=azathioprine treated patients; NT=no actively treated patients; RF=relapse frequency (No of relapses/patient/y); worsened=increase of⩾1 EDSS point. PHC=physical composite score; MHC=mental composite score; RLE=role limitation for emotional reasons.
↵1-150 One patient in NT group dropped out at 6 months.
↵1-151 Significant differences between groups :
Age at entry : NT v AZA p=0.01.
RF at entry : NT v IFN p=0.006.
MHC change : IFN v AZA p=0.006.
RLE change : IFN v AZA p=0.001.
↵1-152 Significant differences within each group (12 monthsv entry):
RF: IFN p<0.001.
AZA p=0.005.